Koa Shoji Holdings Co., Ltd.

Koa Shoji Holdings Co., Ltd.

TTSE:9273
816.00
JPY
-20.00
(-2.39%)
89.00EPS
8.52P/E
31.93BMarket Cap
Feb 11Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
384.37
403.99
395.07
383.81
404.71
449.69
513.73
556.63
556.95
- -
585.94
585.94
Basic EPS, GAAP
29.5
30.52
19.59
16.5
44.05
53.94
59.55
67.83
74.14
- -
89
89
Free Cash Flow per Basic Share
18.97
17.22
31.55
9.71
57.49
77.02
52.86
69.08
96.39
- -
180.25
- -
Dividend per Share
1.1
1.25
1.25
5.82
5.99
8.5
9.98
11.01
11.96
- -
15.98
- -
Book Value per Share
271.91
299.48
327.77
338.45
376.48
421.61
471.14
528.12
594.79
- -
740.3
740.3
Tangible Book Value per Share
271.28
297.73
325.19
336.36
374.04
419.73
469.81
527.27
594.5
- -
740.12
740.12
Basic Weighted Avg Shares
40
37
38
40
40
40
40
40
40
42
42
42
Sales/Revenue/Turnover
15,229
15,133
14,825
15,206
16,034
17,816
20,353
22,053
22,134
- -
24,679
24,679
Operating Margin (%)
11.5
10.67
8.59
7.96
14.53
18.96
18.71
19.27
19.8
- -
22.19
22.19
Depreciation Expense
196
316
467
527
524
626
678
693
726
- -
615
- -
Net Income, GAAP
1,169
1,143
735
654
1,745
2,137
2,359
2,687
2,946
- -
3,749
3,749
Effective Tax Rate (%)
35.1
36.38
43.34
50.2
28.12
37.24
37.15
34.33
32.55
- -
32.15
32.15
Profit Margin (%)
7.67
7.55
4.96
4.3
10.88
11.99
11.59
12.19
13.31
- -
15.19
15.19
Working Capital
5,934
8,913
9,253
9,316
10,682
12,571
14,468
16,596
19,798
- -
18,378
18,378
LT Debt
167
3,753
3,639
3,346
3,024
2,641
2,291
1,941
1,591
- -
972
972
Total Equity
10,773
11,865
12,986
13,409
14,916
16,704
18,666
20,923
25,052
- -
31,180
31,180
Return on Invested Capital (%)
- -
6.85
4.13
3.3
8.82
10.34
10.82
11.67
11.05
- -
- -
- -
Return on Capital (%)
- -
7.93
4.39
3.71
9.53
10.84
11.07
11.65
11.36
- -
- -
- -
Return on Common Equity (%)
- -
10.1
5.91
4.95
12.32
13.52
13.34
13.58
12.82
- -
- -
- -

Capital Structure

JPY

•

in mil. unless spec.
Dec'26
Mar'26
Jun'26
ST Debt
1,214
2,380
2,350
LT Borrowings
1,086
1,045
972
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
42
42
42
Market Capitalization
35,759
34,579
31,926

Working Capital

JPY

•

in mil. unless spec.
Dec'26
Mar'26
Jun'26
Total Current Assets
27,056
25,653
25,330
Cash, Cash Equivalents & STI
13,165
13,548
17,580
Accounts Receivable, Net
5,219
3,810
3,405
Inventories
3,434
3,906
2,841
Total Current Liabilities
5,472
6,084
6,951
Payables & Accruals
- -
- -
- -
ST Debt
1,214
2,380
2,350
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,823
5,560
5,390
5,362
22,134
2025
5,028
7,232
5,361
5,649
- -
2026
5,951
6,703
5,680
6,345
24,679

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
19.12
20.34
17.64
17.21
74.14
2025
18.87
29.78
21.62
16.1
- -
2026
21.18
28.35
22.94
16.53
89

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
11.96
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
15.98

Company Description

CEO
Toshiyuki Shuto
Full Time Employees
318
Sector
Health technology
Industry
Pharmaceuticals: major
Address
13-15, Hiyoshi 7-chome Yokohama KN Japan 223-0061
IPO Date
Jun 21, 2018
Business
Koa Shoji Holdings Co., Ltd. (9273.T) is a Japan-based holding company primarily engaged in the management of subsidiaries focused on the import and sale of active pharmaceutical ingredients (APIs), as well as the manufacture and sale of pharmaceutical products including generic drugs, ethical pharmaceuticals, over-the-counter (OTC) drugs, and health foods; headquartered in Yokohama, Kanagawa, Japan, and established on January 30, 2015. Through its key subsidiaries—Koa Shoji Co., Ltd., which imports and sells generic APIs sourced from over 90 manufacturers in more than 10 countries worldwide and operates a Pharmaceutical Analysis Center for quality assurance and R&D support; Koa Isei Co., Ltd., which manufactures and sells pharmaceuticals mainly consisting of high-potency injections such as anticancer agents, antiemetic agents, pain relievers, agents for pruritic skin diseases, neuropsychiatric agents, agents for metabolic diseases, and anti-rheumatic agents at its facilities in Yamagata including the Zao Factory equipped for vials, syringes, and ampules; and Koa Biotech Bay Co., Ltd., which provides contract packaging of pharmaceutical products, manufactures and sells generic drugs, and markets OTC drugs and health foods—the company operates an integrated business model combining trading and manufacturing to serve generic drug manufacturers, major Japanese pharmaceutical firms, and diverse industry needs with a focus on contract development and manufacturing organization (CDMO) services, stable supply of high-quality low-cost APIs, and self-developed generics targeting cancer, rheumatoid arthritis, and dialysis patients. The group maintains operations primarily in Japan with import networks extending globally, employs 304 people on a consolidated basis as of June 30, 2025, and emphasizes GMP compliance, advanced analytical capabilities, and R&D outsourcing for faster patent expiration items overseas. Recent developments include the 2022 absorption and merger of Koa Pharmaceutical Co., Ltd. by Koa Biotech Bay Co., Ltd., enhancing contract packaging and generic drug production capacities; ongoing expansions such as the 2021 Zao Factory vial production line and Colgate fully automatic ampule packaging operations; and sustained participation in international events like CPHI Frankfurt 2025 and CPHI China 2025 to strengthen global API sourcing and partnerships, alongside a long-term strategy under the "New Business Innovation" slogan to evolve into a specialized API importer and top injectable generic manufacturer potentially via M&A.